Bayer delivers a new CIIE outcome with 'Breakthrough Technologies' and more than a dozen partnership signings

Résumé détaillé

The ninth China International Import Expo came to a close in Shanghai on Nov 10. Attending for the ninth consecutive year, Bayer once again showcased its Pharmaceuticals (with…

The ninth China International Import Expo came to a close in Shanghai on Nov 10. Attending for the ninth consecutive year, Bayer once again showcased its Pharmaceuticals (with Radiology), Consumer Health, and Crop Science divisions, bringing nearly 30 debut exhibits in healthcare and modern agriculture.

Bayer also held and took part in 60 signing ceremonies, achievement releases, and exchange events centered on access to innovative medicines, clinical research, healthcare data and AI, primary care, evidence-based science, and market access, and signed more than 10 partnership agreements. On the heels of that success, Bayer has already signed up for next year's CIIE, moving from nine consecutive editions toward 10 years of "perfect attendance".

Zhou Xiaolan, executive vice-president of Bayer's Pharmaceuticals Division, Bayer AG, president of Bayer Pharmaceuticals China, and president of Bayer China, said: "After nine consecutive years at the CIIE, we are more convinced than ever of the unique value of this platform. It is not only a window into the latest innovations, but also an important bridge connecting global opportunities with China's development, bringing partners together and turning innovative ideas into real-world impact. Bayer has participated in the CIIE every year since its inception and has also benefited greatly from the opportunities it creates.

Début de l'article, extrait de China Daily. Pour lire la suite, ouvrez l'article chez le média.